Ascendas As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the main elements that have enabled Ascendas to become one of the leading business space solutions provider in the country? I…
ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…
China One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr. Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, Neucardin®, which has been shown to improve cardiac function, quality of life and exercise capability, and, to reduce all-cause mortality rates in certain patients suffering…
Medicines Australia We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities, and clinical trials from 2002 to 2012. Are you content looking at the achievements today? Exports still stand at about…
Astellas Austria Whereas most General Managers are exposed to different countries during their professional career, you have chosen to dedicate yours to the Austrian market. What is it in this country so unique that has kept you here over the years? It is a very good question. Since 1974, I have worked…
Department of Industry Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike those in many other industries and the high value of our dollar has brought a sharp focus to industry productivity…
market You established Menarini’s Irish affiliate in 1999. How have you seen the market evolve over these last 13 years? The major changes in the market have principally occurred in the last four or five years, rather than the previous ten. Generally speaking, the industry has always had a very strong…
AstraZeneca Australia You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at the overall market, the biggest changes have been the various reforms to the Pharmaceutical Benefits Scheme (PBS). PBS reform started…
MSD In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North America, Western Europe and Japan. Today, emerging markets contribute to around 18% of MSD’s total revenues. For the next 5…
Albany Molecular Research Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing opportunities in drug discovery. I worked for a few years in business development with Dishman and although I enjoyed this…
Novo Nordisk - Belgium Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager of Novo Nordisk BeLux less than a year ago. What motivated you to join the company back in 2010 and…
Oystershell Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated this decision and how you have transformed the company in the 10 years since? Over time, it had become clear…
See our Cookie Privacy Policy Here